BiotechTube

Dapagliflozin/sitagliptin FDC + Sitagliptin + Dapagliflozin

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)

Conditions

Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)

Trial Timeline

Mar 21, 2022 → May 31, 2022

NCT ID
NCT05266404

About Dapagliflozin/sitagliptin FDC + Sitagliptin + Dapagliflozin

Dapagliflozin/sitagliptin FDC + Sitagliptin + Dapagliflozin is a phase 1 stage product being developed by AstraZeneca for Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus). The current trial status is completed. This product is registered under clinical trial identifier NCT05266404. Target conditions include Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus).

What happened to similar drugs?

20 of 20 similar drugs in Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus) were approved

Approved (20) Terminated (1) Active (0)
✅Cholestyramine + Colesevelam HClDaiichi SankyoApproved
✅Cholestyramine + Cholestyramine + TangDaiichi SankyoApproved
✅Olmesartan medoxomil + Irbesartan + ValsartanDaiichi SankyoApproved
✅Perampanel 6 MGEisaiApproved
✅eszopiclone, zolpidem, placeboSumitomo PharmaApproved
✅Listerine Experimental Mouthwash + Colgate Cavity Protection Toothpaste + Listerine Total Care ZeroJohnson & JohnsonApproved
✅Listerine Clinical Solutions Teeth Strength + Listerine Total Care Zero Alcohol Mouthwash + Colgate Cavity Protection ToothpasteJohnson & JohnsonApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05266404Phase 1Completed

Competing Products

20 competing products in Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
29
ValsartanNovartisPhase 1
29
CSL112 + PlaceboCSLPhase 1
29
UT-15CUnited TherapeuticsPhase 1
26
VNA-318 + PlaceboBiotrialPhase 1
19
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
19
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
19
Radiolabeled TRV130TrevenaPhase 1
19
TRV130A + Dextrose in WaterTrevenaPhase 1
19
TRV734TrevenaPhase 1
19
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
29
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
29
KPL-404Kiniksa PharmaceuticalsPhase 1
23
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
29
Propranolol + PseudoephedrineEli LillyPre-clinical
26
LY2157299Eli LillyPhase 1
29
Lasmiditan + PlaceboEli LillyPhase 1
29
LY3015014 + PlaceboEli LillyPhase 1
29
LOXO-783Eli LillyPhase 1
29
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
29